Colorectal Cancer Clinical Trial
Official title:
Screening for Colorectal Cancer in Average and High Risk Iraqi Population: A Pilot Study
The existing evidence from epidemiological studies and randomized controlled trials has
consistently assures the cost effectiveness and the influential role of screening in reducing
incidence rates and deaths caused by Colorectal Cancer (CRC). Population based organized
screening programmes, which should be considered an obligation that is not to be postponed,
require valuable information that can be reliably extrapolated from well-designed pilot study
conducted prior to programme implementation.
The main objectives of the current pilot CRC screening project, named after "Al-Kindy College
of Medicine", was to evaluate and explore the specific aspects of the intended
population-based organized CRC screening programme, including: barriers affecting adherence
to the programme, performance indicators of the proposed screening programme, the target
population in which CRC screening is a legitimate healthcare priority, quality assurance of
screening tests and colonoscopy services, and to propose an algorithm that will provide a
clinically and logistically acceptable positivity rate.
Screening Type and Setting :
"Al-Kindy College Colorectal Cancer Screening Project", is proposed as an FIT-based
colorectal cancer screening, with colonoscopy being used as the second stage investigation in
those with a positive FIT result. This screening project was set as a 24 months pilot study,
to be started in April 2015 and extended to May 2017. All the investigations and evaluation
measures involved were performed in the scientific research laboratory and endoscopy unit of
Al Kindy polyclinic at Al Kindy College of Medicine, University of Baghdad. Baghdad, Iraq.
Study Protocol:
Target Individuals and Eligibility:
The target individuals of the present study are residents of Baghdad city being ≥45 years of
age with stop age of 80 years. target individual with fulfill devoid of exclusion criteria is
identified as eligible.
Invitation of Eligible Individuals:
Due to the lack of a population register, invitation for the proposed screening programme was
based on two approaches, namely, household open invitation (HOI), and recommendation by
physician (RBP).
1. Household-Open Invitation (HOI): A survey sheet, which all together serves as an
invitation letter, was assembled competently. The first part of the sheet, in Arabic
language, included introductory information about CRC incidence and risk factors, CRC
screening benefits and meaning of test results, along a briefly description for the
potential diagnostic tests and treatment options. The second part aimed to document
information about the invited families, including demographic data, the number of target
individuals and their eligibility, as well as the prevalence of CRC risk factors
including: body mass index (BMI), smoking and alcohol intake, type2 diabetes mellitus
(T2DM) and family history of CRC. Total of 1000 survey sheets were delivered by 10
teams, each team consist of 10 well-trained 4th stage students of Al Kindy College of
Medicine, as part of their epidemiology training course. The dissemination was planned,
in an order of 100 families per week, with as possible equity to ensure the coverage of
all municipalities of Baghdad city. Students were requested to return the day next to
delivery, to check for the eligibility of target individuals and participation consent.
2. Recommendation By Physician (RBP): A random survey of 1000 outpatients, attending
Endocrine Disease Treatment Center, Baghdad, Iraq, was arranged with the aim of
encouraging patients who fulfil the criteria for eligibility to participate in the
screening programme. Referral forma including participation consent was issued, as an
act on acceptance, and the issued referral forma were documented to measure patients'
compliance.
Enrollment of Participants in the Proposed Screening Programme:
Screenees' basic information and progressive examination outcomes were documented through a
comprehensive "Audit and Tracking Sheet", divided into the following four major disciplines:
1. Characteristics and Risk Stratification:
To evaluate the impact of risk stratification on screenee's behavior and on the
effectiveness of the screening project, participants were divided into three risk groups
based on survey and medical record data: high-risk (history of polyps, and/or
personal/family history of CRC, increased-risk (diabetes, obesity, and/or former or
current smoking status), and average-risk (45 or older with no other risk factor).
2. FIT and Colonoscopy Tracking Screening Schedule:
After checking for sampling appropriateness, the received samples were analyzed by the
FOB Gold/SENTiFOB method (Sentinel Diagnostics SpA, Milan, Italy), according to the
previously validated procedural platform.
In case of first FIT incompletion, the cause is identified and the screenees were
encouraged for re-enrollment. Timely referral to colonoscopy was based on FIT level
≥75ng/ml in any of the two collected samples. Negative FIT-tested individuals with high
risk stratification were also encouraged to be enrolled. On approval, after a brief
elucidation for the pros and cons, screenees were scheduled for conventional
colonoscopy.
Considering the reported improved patient tolerance of sodium picosulphate preparations
(PICOPREP, Ferring Pharmaceutical Co., Ltd., Zhongshan, China), this cleansing agent was
preferentially prescribed.Detailed oral and written instructions on how to perform the
bowel cleansing regimen was provided, with an excellent opportunity to answer any
questions the screenee may have, to ensure that the process was appropriately
understood.
With the colonoscopists completely blinded regarding the FIT results, conventional
colonoscopy examinations were conducted in the Endoscopy Unit of Al-Kindy Polyclinic.
For non-compliance, the cause of cancelled appointment was identified, and screenees
were reinvigorated for a rescheduled appointment. For attendants, on the other hands,
the final examination report must verify the completeness of colonoscopy; otherwise, the
report should point to the cause of incompleteness. The report should also document the
number, size, type and anatomical location of any screen-detected lesions.
3. Histological Report of Lesion Biopsies and Resections:
Histopathological examinations of screen-detected lesions were performed by skilled
pathologists in gastrointestinal disease with specific emphasis on colorectal cancer,
along a good expertise in the preparation and interpretation of biopsies and endoscopic
polypectomy specimens.
Classification of adenomas included grading of neoplasia was accomplished according to
the revised Vienna classification that has been modified for the European Guidelines to
obtain a two- tiered system of low-grade and high-grade neoplasia.. Furthermore, and
whenever applicable, the correlation between histological diagnosis of biopsy and
resection specimens were included in the final examination reports.
If more than one lesion is found, lesion with the worst prognosis is indicated as the
final colonoscopic outcome and will be used for evaluation purposes. Based on the number
and characteristics of adenomas detected at baseline colonoscopy, screenees were
stratified into low, intermediate, and high risk polyp for the development of colorectal
cancer. Screenees with intermediate and high risk were referred to a follow-up
surveillance programme. Positive FIT results in participants who were identified with no
adenomas, advance adenomas, or adenocarcinomas on subsequent colonoscopies are
considered False-positive fecal immunochemical tests (FP-FIT) results.
4. Quality Assurance of Screening Programme:To ensure a potential benefit of colorectal
cancer screening, quality assurance of the programme was assessed at every step in the
process, including the FIT sampling regimen, precolonoscopy cleansing regimen, bowel
preparation quality using the Ottawa bowel preparation scale (OBPS), as well as
colonoscopy quality with special emphasis on colonic mucosa inspection and the safety
and tolerance of colonoscopy.
Data Processing and Statistical Analysis:
All Data analysis was processed by the statistical package SPSS version 21.0 (SPSS, Inc.).
Descriptive and categorical variables were presented as frequencies and percentages, and
Fischer's exact test was performed to inspect any association between these variables.
Indicators of screening performance for FIT (including participation rate, and positivity
rate) and colonoscopy (including compliance rate, completion rate, lesions detection rate,
adenoma detection rate, advanced adenoma detection rate, and cancer detection rate), in
addition to the positive predictive value (PPV) for detection of lesions, adenoma, advanced
adenoma, and cancer, were all calculated according to the European guidelines for quality
assurance in colorectal cancer screening and diagnosis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |